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Received November 5, 2013; accepted December 11, 2013AbstractBackground: Many researchers have focused on developing traditional herbal medicines as pharmacological medicines to treat hepatic fibrosis. In
this study, we evaluated the possible mechanism of Ger-Gen-Chyn-Lian-Tang (GGCLT) on thioacetamide (TAA)-induced hepatic injury in mice.
Methods: Hepatic fibrosis mice were established by intraperitoneal injection with TAA (100 mg/kg, 3 times/week), and treated with daily oral
administration of 30 mg/kg, 100 mg/kg, and 300 mg/kg of GGCLT for 6 weeks. There were 40 mice randomly assigned to control, TAA and
TAAþGGCLT groups. When the experiment was completed, Masson’s trichrome staining was used to measure the degree of liver fibrosis.
Hepatic fibrosis molecules were assessed by Western blot and real-time polymerase chain reaction. Hepatic glutathione levels, matrix metal-
loproteinase (MMP-2 and MMP-9), and hydroxyproline were also measured.
Results: Treatment with GGCLT significantly reduced the toxicity of TAA and exhibited effective hepatoprotective activity. The mechanism of
the hepatoprotective effect of GGCLT is proposed to be by normalizing oxidative stress. Additionally, the data of fibrotic areas, expression of
procollagen III, and MMP2 and 9 mRNA levels in the TAAþGGCLT group were much lower than those in the TAA group (p < 0.05).
Furthermore, the upregulation of hepatic protein levels of nuclear factor-kB, transforming growth factor (TGF)-b receptor-1, and smooth muscle
a-actin induced by TAA was significantly inhibited after GGCLT treatment.
Conclusion: GGCLT can efficiently ameliorate hepatic fibrosis by its inhibitory effects on the intrahepatic oxidative stress in TAA mice model.
The antioxidant properties afforded by GGCLT may be attributed to its modulation on TGF-b/TGFb receptor signaling through the down-
regulation of integrated signal pathways involving smooth muscle a-actin and lipid peroxidation.
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Liver fibrosis represents the consequences of a sustained
wound healing response to various chronic liver injuries
including viral, autoimmune, drug-induced, cholestatic, and
metabolic diseases.1 This process is associated with the
increased expression of contractile filaments such as smooth
muscle a-actin (a-SMA) and production of extracellularociation. All rights reserved.
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such as cytokines and reactive oxygen species.2 During he-
patic fibrogenesis, transforming growth factor (TGF)-b1 plays
a pivotal role in the progression of liver fibrosis by promoting
the transdifferentiation and migration of hepatic stellate cells
(HSCs).3,4
Although the modern medicinal system has undergone
phenomenal development, discovering a new drug for treating
liver diseases remains a distant reality. Therefore, a number of
therapeutic plants are used in the traditional system of medi-
cine for the management of liver disorders. However, many of
them have not been formally investigated for their efficacy and
possible side effects. Ger-Gen-Chyn-Lian-Tang (GGCLT) is a
traditional extract mixture of four Chinese medicine herbs,
consisting of Puerariae Radix, Coptidis Rhizoma, Scutellariae
Radix, and Glycyrrhizae Radix. GGCLT is used to control
inflammatory response,5 and the actions partly by the major
constituents of GGCLT. Puerarin, derived from Pueraria
lobata,6e8 baicalin, an active component of Scutellaria
baicalensis,9e11 berberine, the major alkaloid of the Coptis
chinensis,12,13 and glycyrrhizin from Glycyrrhiza ura-
lensis,14,15 all exhibit antioxidant properties and have been
shown to ameliorate hepatic injury in earlier studies.8e11,13e15
Alternative medicines for chronic liver disease, mostly
herbal preparations from single or multiple plants, can be
traced back through ancient China and hold promise for the
development of cheap and potentially low-risk natural drugs.
Compared to many studies currently focusing on the discovery
of therapeutic pure compounds, the application of mixed-type
Chinese medicine in treating liver disease is still limited and
requires more extensive investigation. In this study, we addressFig. 1. The chromatogram of four reference standards was shown in high-performan
Tang injection. Four main index components were recognized by comparing the rete
puerarin, berberine, baicalin, and glycyrrhizin, which represented Puerariae Radixwhether mix product GGCLT could have a beneficial effect in
hepatic fibrosis. GGCLT is an officially approved standardized
remedy available in Taiwan and widely used as a health
medicine in Chinese society. Thus, identifying new therapeutic
uses and effects of GGCLT would accelerate its beneficial use
in the larger society. To address this issue, the antioxidant
property of GGCLT was evaluated in TAA-induced hepatic
injury in mice.
2. Methods2.1. Preparation of GGCLTGGCLT powder consists of crude ingredients extracted
from the following four medicinal herbs mixed in the ratio in
parenthesis: Puerariae Radix (roots of Pueraria lobata, Ge
Gen), Scutellariae Radix (roots of Scullellaria baicalensis,
Huang Qin), Coptidis Rhizoma (rhizomes of Coptis chinensis,
Huang Lian), and Glycyrrhizae Radix (roots of Glycyrrhiza
uralensis, Gan Cao) with a ratio of 8:3:3:2 in weight. The
GGCLT was prepared by boiling the dried powder with
distilled water for 2 hours at 80C. The resulting extract was
filtered and lyophilized (VirTis Freezemobile, Gardiner, NY,
USA) to a light-brownish residue with an approximate yield of
12.5% (w/w). These substances were freeze-dried, and kept at
e20C. The dried extract was dissolved in distilled water
before use. The high-performance liquid chromatography
(HPLC) chromatogram of three reference standards was
shown in HPLC profiles of GGCLT injection (Fig. 1). The four
main index components of the GGCLT decoction were
recognized by HPLC. The analytic column was Cosmosil C18ce liquid chromatography-UV profiles of raw material of Ger-Gen-Chyn-Lian-
ntion times and UV spectra with standards of compound (lower). The peaks are
, Scutellariae Radix, Coptidis Rhizoma, and Glycyrrhizae Radix, respectively.
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mixture of 0.03% phosphoric acid-water-acetonitrile. The flow
rate was 1.0 mL/minute, 20 mL of solution was injected into
HPLC system for analysis. Puerarin, berberine, baicalin, and
glycyrrhizin are represented by Puerariae Radix, Scutellariae
Radix, Coptidis Rhizoma, and Glycyrrhizae Radix, respec-
tively (Fig. 1).2.2. Animals and experimental designsPeritoneal injection of TAA (Sigma Chemical Co., St.
Louis, MO, USA) was employed to induce liver injury
(100 mg/kg every 2 days for 6 weeks). Male C57BL/6 mice
were purchased from the National Laboratory Animal Center
(Taipei, Taiwan). All animals were housed in a controlled
environment and allowed free access to food and water. The
animal studies were approved by the Animal Experiment
Committee of Chang Gung University, Taoyuan, Taiwan
(IACUC Approval No.: CGU12-135) and conducted in
accordance with the Guide for the Care and Use of Laboratory
Animals. Mice were randomized into three groups: control,
TAA, and TAAþGGCLT groups (8 animals in each group).
The TAAþGGCLT group received TAA plus GGCLT (30 mg/
kg/day, 100 mg/kg/day, or 300 mg/kg/day) by gastric gavage
from the initiation of TAA administration. The TAA group
received TAA plus normal saline administration. The mice in
each group were sacrificed under anesthesia at the end of the
experiments. Portions of liver tissues were fixed in 10%
neutral buffered paraformaldehyde for histopathologic and
immunohistochemical examinations, or immediately frozen in
liquid nitrogen and stored at 80C for further RNA and
protein analysis. Serum was collected and stored at 20C
until analysis.2.3. Histopathology assay and biochemical
measurementThe liver tissue was fixed in 10% formalin and then
embedded in paraffin, cut into 5-mm thick sections, and stained
with Masson’s trichrome, and then examined under light mi-
croscopy by an experienced pathologist. Then, blood was
obtained for serum biochemical analysis, and the activities of
alanine aminotransferase (ALT) were measured using an Auto
Dry Chemistry Analyzer (Hitachi 736-60, Tokyo, Japan).
The liver homogenate for lipid peroxidation was prepared
with 2 mL of 50mM potassium phosphate buffer, pH 7.4, and
thiobarbituric acid-reactive substances (TBARS) were deter-
mined.16 The fluorescence of the samples was detected at an
excitation wavelength of 515 nm and an emission wavelength
of 555 nm in a F4500 fluorescence spectrophotometer (Hita-
chi, Japan). 1,1,3,3-Tetramethoxypropane was used as the
TBARS standard. Results were expressed in nmol/mg protein,
and protein concentrations were determined by the method of
Lowry et al.17
Hepatic hydroxyproline content was measured using a
modified version of the method of Jamall et al.18 Briefly, liver
samples were homogenized and hydrolyzed in 6N HCl at110C for 18 hours. After filtration of the hydrolysate through
a 0.45-mm Millipore Filter (Millipore, Bedford, MA, USA),
chloramine T was added to a final concentration of 2.5mM.
The mixture was then treated with 410mM paradimethyl-
amino-benzaldehyde and incubated at 60C for 30 minutes.
After cooling to room temperature, the samples were read at
560 nm against a reagent blank which contained the complete
system without added tissue. The concentration of hydroxy-
proline in each sample was determined from a standard curve
generated from known quantities of hydroxyproline.
Hepatic levels of glutathione were determined using a
glutathione-400 colorimetric assay kit (Calbiochem Co., San
Diego, CA, USA) and performed by using a spectrophotom-
eter as in our previous study.19 Liver tissue was homogenized
with 2 mL of 10% (w/v) metaphosphoric acid solution at 4C.
Each sample was then centrifuged at 3000g for 10 minutes at
4C. After each sample was vortexed, 50 mL aliquot of the
centrifuged supernatants were added to the assay buffer pro-
vided by the manufacturer until the volume was the equivalent
of 200 mL. The reaction mixtures were incubated at 25C for
30 minutes, and were measured by a spectrophotometer at
412 nm. The values of unknown samples were drawn from a
standard curve plotted by assaying different known concen-
trations of glutathione (GSH). The amounts of GSH were
expressed as nmol/mg protein.2.4. Western blottingThe liver tissue was lysed with distilled water containing
protease inhibitors (BD Pharmingen, San Jose, CA, USA), and
a Bio-Rad (Hercules, CA, USA) rapid Coomassie kit was used
to determine the total protein concentration. Samples of 60 mg
protein were run on a 10% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis gel followed by Western blot-
ting with various mouse or rabbit monoclonal antibodies
TGFb-R1, TGFb-R2, and a-SMA from Santa Cruz (Santa
Cruz Biotechnology, Santa Cruz, CA) or Histone H1 and anti-
nuclear factor(NF)-kB antibody (Chemicon, Temecula, CA,
USA). Chemiluminescence (ECL; Amersham, Piscataway, NJ,
USA) in conjunction with video densitometry was used to
quantify protein expression.2.5. Real-time polymerase chain reaction analysisTotal RNA was extracted from the hepatic tissue using the
guanidinium-phenol- chloroform method. Total RNA (5 mg)
was reverse-transcribed using the RevertAid First Strand
cDNA Synthesis kit (Thermo Fisher Scientific, Waltham, MA,
USA) according to the manufacturer’s instructions. The cDNA
was amplified using the TaqDNA polymerase kit (Fermentas,
Vilnius, Lithuania). Real-time polymerase chain reaction was
performed on a LightCycler 1.5 apparatus (Roche Diagnostics
GmbH, Basel, Switzerland) using the LightCycler FastStart
DNA MasterPLUS SYBR-Green I kit according to the man-
ufacturer’s protocol. cDNA synthesis was achieved with Su-
perScript III reverse transcriptase (Invitrogen, Carlsbad, CA,
USA). Commercially available primers were purchased from
363Z.-Y. Chang et al. / Journal of the Chinese Medical Association 77 (2014) 360e366Purigo Biotech, Inc. (Taipei, Taiwan R.O.C.) The primer pairs







GGAAAGAAGTCTGAGGAATGC.2.6. Statistical analysisThe results are expressed as mean  standard error of the
mean. Quantitative variables were tested with analysis of
variance rank KruskaleWallis tests. A p value of < 0.05 was
considered to be statistically significant (Statsoft Statisica 3.1,
Tulsa, OK, USA).
3. Results3.1. GGCLT improved liver fibrosisAs shown in Fig. 2, TAA treatment mice had abundant
fibrosis showing a characteristic pattern of perivenular and
periportal deposition of collagen fiber with the development of
portal-to-portal septa. However, mice that received GGCLT
displayed thinner septa of collagen and more preserved he-
patic parenchyma than the mice with untreated TAA. This
result was confirmed by the Western blot analysis of a-SMA
(Fig. 3B) in which samples from the mice receiving chronic
GGCLT treatment showed a significant reduction in the per-
centage of fibrosis area as compared to samples from TAA
mice. The percentage of liver tissue that showed a reduction in
the TGFb-R1 level after GGCLT treatment when compared to
the untreated TAA mice is shown in Fig. 3C and D. The
fibrosis was also evaluated histologically by visualizing fibersFig. 2. Light microscopic analysis of mice liver sections of normal mice, and aft
administration. (A, D) Normal mouse liver; (B, E) TAA alone; and (C, F) TA
weeks. Paraffin embedded sections were stained with Masson’s trichrome. The oriof collagen in sections of liver samples stained with Masson’s
trichrome (Fig. 2). This histopathological analysis is consistent
with the results for a-SMA (Fig. 3B), TGF-bR1 (Fig. 3C), and
TGF-bR2 (Fig. 3D) which were evaluated using Western blot
analysis. a-SMA and TGF-bR1 were elevated significantly
after the TAA treatment but decreased partially but signifi-
cantly by treatment with GGCLT.
Additionally, we examined the effect of GGCLT on hepatic
mRNA expression of TGF-b, a marker of HSC activation.
There is procollagen III, a fibril-forming collagen that pre-
dominates in chronic liver disease, and MMP-2, a matrix
metalloproteinase that degrades collagen and MMP-9. As
shown in Fig. 4, TGF-b, procollagen III, MMP-2, and MMP-9
levels were significantly upregulated in TAA mice receiving
GGCLT treatment as compared to untreated TAA animals.3.2. Induction of intracellular glutathione in GGCLT-
treated TAA miceTo evaluate the effect of GGCLT on the underlying mecha-
nism of the TAA-induced hepatic damage, the activity of the
NF-kB proteins was examined. The expression of NF-kB was
significantly decreased by GGCLT treatment in TAA mice
(Fig. 3A). Additionally, the induction of lipid peroxidation in
TAAmicewas dramatically reduced by treatment with GGCLT,
whereas theGSH levels also changed. These data indicate that at
least the antioxidant effects of GGCLTare involved in the TAA-
mediated oxidative stress. As expected, a significantly lower
GSH concentration was found in the liver tissue from TAAmice
as compared to the normal group (Fig. 5D). GGCLT treatment
led to much higher concentrations of total GSH in the liver than
those found in TAA mice. Notably, the significant increase in
GSHconcentrationwas associatedwith a decrease in the level of
the lipid peroxidation marker TBARS (Fig. 5C). The inhibition
of oxidative stress exhibited by GGCLT has been associated
with lipid peroxidation inhibition and the subsequent decreaseer thioacetamide (TAA) treatment with or without Ger-Gen-Chyn-Lian-Tang
A concomitantly treated with Ger-Gen-Chyn-Lian-Tang (300 mg/kg) for 6
ginal magnification was 200. H&E stain ¼ hematoxylin and eosin stain.
Fig. 3. Western blot analysis of (A) hepatic nuclear factor (NF)-kB, (B) smooth muscle a-actin (a-SMA), (C) transforming growth factor b receptor (TGF-bR)1,
and (D) TGF-bR2 protein contents of normal mice, in mice after TAA treatment, with thioacetamide and Ger-Gen-Chyn-Lian-Tang (30 mg/kg, 100 mg/kg,
300 mg/kg) administration after thioacetamide injection for 6 weeks. Liver homogenate fractions (60 mg protein/lane) were analyzed for immunoreactivity with an
antibody-recognizing specific antibody. The membranes were also probed with an antibody-recognizing b-actin to assure equal protein loading in the respective
lines. The gels are representative of three experiments from separate animals.
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levels of ALT (Fig. 5A) and hydroxyproline (Fig. 5B) were
significantly lower than those of the TAA group (p < 0.05).
4. Discussion
Natural Chinese medicine has an extensive history of use in
Taiwan and comprises mixed-type ingredients. Compared to
many studies focusing on the discovery of therapeutic pure
compounds, application of mixed-type Chinese medicine inFig. 4. Ger-Gen-Chyn-Lian-Tang (GGCLT) attenuated hepatic fibrogenesis
factors of thioacetamide treatment mice. The effects of GGCLT on (A)
transforming growth factor (TGF)-b1, (B) matrix metalloproteinase (MMP)-2,
(C) MMP-9, and (D) procollagen III transcription levels. The mRNA levels
were analyzed by real-time polymerase chain reaction. * p < 0.05 compared
with lean control group; ** p < 0.05 compared with thioacetamide mice
without GGCLT treatment.treating liver injury is still limited and needs more extensive
investigation. GGCLT mix product is an officially approved
standardized remedy available in Taiwan and widely used as a
health medicine in Chinese society. GGCLT is used to control
inflammatory response,5 and this benefit is primarily ascribed
to the actions of some major constituent flavonoids in GGCLT.
Puerarin,6e8 baicalin,9e11 berberine,12 and glycyrrhizin14 all
exhibit anti-inflammatory activity and were shown to
ameliorate tissue damage following inflammation. This in-
cludes the prevention of brain infarction, inhibition of
ischemic brain injury, alcoholism, and liver steatosis. More-
over, the hepatoprotective properties of puerarin, baicalin, and
glycyrrhizin have also been demonstrated.8e10,14
The principle findings of this study relate to a potential
mechanism of GGCLT that is linked with hepatic fibrogenesis.
These data suggest that the mechanistic inhibition of hepatic
oxidative stress would attenuate fibrosis in chronic liver dis-
ease. The bases of these theories are discussed in the following
paragraphs.4.1. Antifibrotic mechanisms of GGCLT include
stimulation of the hepatic antioxidant defensesThe induction of fibrosis by TAA occurs in vivo and is
believed to involve the generation of oxidative stress,20e22 and
an imbalance between fibrosis and antifibrosis signaling
pathways.
Several reports have shown that the oxidative stress asso-
ciated with lipid peroxidation is involved in the development
Fig. 5. Ger-Gen-Chyn-Lian-Tang (GGCLT) attenuated oxidative stress and restored glutathione (GSH) in the liver of thioacetamide treated mice. The effects of
GGCLT on (A) alanine aminotransferase levels (ALT), (B) hydroxyproline concentrations, (C) thiobarbituric acid reactive substances (TBARS) content, and (D)
GSH levels. * p < 0.05 compared with control group; ** p < 0.05 compared with thioacetamide treatment without GGCLT treatment.
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that administration of GGCLT reduced the increased levels of
plasma ALT after TAA challenge. Additionally, GGCLT
decreased the oxidative stress and the decreased levels of
TBARS, as compared to the TAA treated mice. In the current
study, the levels of TBARS and hydroxyproline were signifi-
cantly elevated due to TAA, whereas GGCLT treatment
markedly reduced these marker levels, which tended to
decrease with GGCLT treatment. This also supports the hy-
pothesis that GGCLT ameliorates liver injury through its
antioxidant effect. GSH is an essential component of the
cellular defense mechanism against oxidative stress that is
induced by reactive oxygen species in rats with TAA.22,26e28
The restoration of hepatic GSH levels by GGCLT treatment
could in part be related to its antioxidant and free-radical
scavenging effect. Another explanation for this statistically
significant increase in the GSH levels seen in the GGCLT
treated mice compared with the TAA group is the effect of
GGCLT on the enzymes involved in GSH synthesis, whereby
GGCLT may help to maintain the levels of glutathione during
oxidative stress. Additionally, GGCLT has the ability to elicit
hepatoprotective effects by enhanced tissue GSH expression
and lower ALT levels, which is consistent with the data
showing decreased TBARS levels. Our results suggest that the
upregulation of TBARS in the liver may increase hepatic tis-
sue susceptibility to harmful stimuli and may cause the dete-
rioration of liver functions. The change in TBARS expression
after GGCLT treatment may account for the attenuation of the
cellular functions by ameliorating oxidative stress stimuli in
TAA-treated mice.4.2. Possible mechanism revealed that TGFb signaling
might be involved in the anti-fibrotic action of GGCLTThe aspect of liver injury brought on by TAA is mediated
through oxidative stress, which can cause dysfunction of he-
patocytes and the discharge of inflammation-related cytokines
as NF-kB and IL-6 and fibrogenic mediators as TGF-b1.
Intracellular oxidative stress may be a relevant contributor to
fibrogenesis, as well as TGF-b expression. However, NF-kB
may play an essential role in the activation of HSCs, which bind
to the specific regulating sequence of the a-SMA gene. The
present study revealed that GGCLT treatment attenuated the
level of prominent profibrogenic gene TGF-b1 expression. This
indicates the inhibitory activity of GGCLT to the proliferative
activity of HSCs, which might be confirmed by reduced
collagen deposition in the liver tissues of animals treated with
GGCLT. Similarly, the high levels of NF-kB observed in the
fibrosis group mice were reversed in the mice treated with
GGCLT indicating the anti-inflammatory activity of GGCLT.
For the first time, GGCLT has also been shown to inhibit TGF-b
levels, probably by its inhibitory action on the NF-kB pathway.
Moreover, GGCLT may attenuate HSC activation via the
downregulation of TAA-induced a-SMA, and TGF-b signaling
activation. The enhancement by GGCLT of GSH production,
and the inhibition of MMP-2 and MMP-9 production by HSCs
seem to be additional mechanisms of its antifibrotic activity.
Indeed, our results demonstrate that hepatocellular injuries
are reduced by the GGCLT treatment of TAA mice, are asso-
ciated with TGFb and a-SMA activities, and involve hepatic
GSH levels. Our current observations suggest that GGCLTplays
366 Z.-Y. Chang et al. / Journal of the Chinese Medical Association 77 (2014) 360e366a role in attenuating hepatic fibrosis in the initiation and
perpetuation of HSC activation. The expression of two well-
characterized and validated markers of the initiation phase of
HSC activation,a-SMA andTGF-b, were decreased inGGCLT-
treated TAA mice. Likewise, the markers for the perpetuation
phase of stellate cell activation, procollagen III and TIMP
transcripts, were also diminished in the presence of GGCLT.
The studies have implicated dysregulation of the TGF-b
signaling in various liver diseases and their complications
(e.g., hepatitis, fibrosis, cirrhosis, and ischemiaereperfusion).
This observation raised the possibility that the pharmacolog-
ical modulation of the hepatic TGF-b signaling could be a
valuable therapy in cases of hepatic injury. In the current
study, we alternatively investigated whether GGCLT attenu-
ated the activation of hepatic TGF-b signaling receptors in
mice with pre-existing fibrosis decreased hepatic collagen
abundance and, therefore, reversed fibrosis. Our study reveals
a potential, crucial antifibrogenic role of the administration of
GGCLT efficiently reducing fibrogenesis, and may open new
therapeutic avenues for the treatment of liver fibrosis.
In conclusion, we have demonstrated the antifibrosis effect of
GGCLTand its molecular mechanism. GGCLT protects hepatic
cells from TAA-induced damage via the amelioration of oxida-
tive stress status. This molecular action suggests that GGCLT
may prove useful as a research tool or in clinical applications.
Acknowledgments
This work was supported in part by grants from the Na-
tional Science Council Taipei, Taiwan, NSC 101-2320-B-182-
017- (T.Y.L.), and the research grant from the Chang Gung
Memorial Hospital, CMRPG2C0291 (Z.Y.C.) and
CMRPG2C0491 (T.H.H.).
References
1. Friedman SL. Liver fibrosisdfrom bench to bedside. J Hepatol
2003;38(Suppl 1):S38e53.
2. Thomas P, Petrick AT, Toth CA, Fox ES, Elting JJ, Steele Jr G. A peptide
sequence on carcinoembryonic antigen binds to a 80kD protein on Kupffer
cells. Biochem Biophys Res Commun 1992;188:671e7.
3. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver
fibrosis suggest stellate cells and TGF-beta as major players and thera-
peutic targets. J Cell Mol Med 2006;10:76e99.
4. Yang C, Zeisberg M, Mosterman B, Sudhakar A, Yerramalla U,
Holthaus K, et al. Liver fibrosis: insights into migration of hepatic stellate
cells in response to extracellular matrix and growth factors. Gastroen-
terology 2003;124:147e59.
5. Tang SY, Whiteman M, Peng ZF, Jenner A, Yong EL, Halliwell B.
Characterization of antioxidant and antiglycation properties and isolation
of active ingredients from traditional Chinese medicines. Free Radic Biol
Med 2004;36:1575e87.
6. Chang Y, Hsieh CY, Peng ZA, Yen TL, Hsiao G, Chou DS, et al. Neu-
roprotective mechanisms of puerarin in middle cerebral artery occlusion-
induced brain infarction in rats. J Biomed Sci 2009;16:9.
7. Xu XH, Zhao TQ. Effects of puerarin on D-galactose-induced memory
deficits in mice. Acta Pharmacol Sin 2002;23:587e90.
8. Zhang Z, Li S, Jiang J, Yu P, Liang J, Wang Y. Preventive effects of Flos
perariae (Gehua) water extract and its active ingredient puerarin in rodent
alcoholism models. Chin Med 2010;5:36.9. Park SW, Lee CH, Kim YS, Kang SS, Jeon SJ, Son KH, et al. Protective
effect of baicalin against carbon tetrachloride-induced acute hepatic injury
in mice. J Pharmacol Sci 2008;106:136e43.
10. Guo HX, Liu DH, Ma Y, Liu JF, Wang Y, Du ZY, et al. Long-term baicalin
administration ameliorates metabolic disorders and hepatic steatosis in
rats given a high-fat diet. Acta Pharmacol Sin 2009;30:1505e12.
11. Yang MD, Chiang YM, Higashiyama R, Asahina K, Mann DA, Mann J,
et al. Rosmarinic acid and baicalin epigenetically derepress peroxisomal
proliferator-activated receptor g in hepatic stellate cells for their anti-
fibrotic effect. Hepatology 2012;55:1271e81.
12. Abd El-Wahab AE, Ghareeb DA, Sarhan EE, Abu-Serie MM, El
Demellawy MA. In vitro biological assessment of berberis vulgaris and its
active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-
diabetic and anticancer effects.BMCComplement AlternMed 2013;13:218.
13. Chao J, Liao JW, Peng WH, Lee MS, Pao LH, Cheng HY. Antioxidant,
analgesic, anti-Inflammatory, and hepatoprotective effects of the ethanol
extract of Mahonia oiwakensis stem. Int J Mol Sci 2013;14:2928e45.
14. Gumpricht E, Dahl R, Devereaux MW, Sokol RJ. Licorice compounds
glycyrrhizin and 18beta-glycyrrhetinic acid are potent modulators of bile
acid-induced cytotoxicity in rat hepatocytes. J Biol Chem 2005;280:
10556e63.
15. Nose M, Terawaki K, Iwahashi N, Oguri K, Ogihara Y. Comparative study
of the high molecular mass fraction and low molecular mass fraction of
Sho-saiko-to in a murine immunologically induced liver injury model.
Biol Pharm Bull 2002;25:64e7.
16. Fraga CG, Leibovitz BE, Tappel AL. Lipid peroxidation measured as
thiobarbituric acid-reactive substances in tissue slices: characterization
and comparison with homogenates and microsomes. Free Radic Biol Med
1988;4:155e61.
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement
with the Folin phenol reagent. J Biol Chem 1951;193:265e75.
18. Jamall IS, Finelli VN, Que Hee SS. A simple method to determine
nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem
1981;112:70e5.
19. Lee TY, Chang HH, Wang GJ, Chiu JH, Yang YY, Lin HC. Water-soluble
extract of Salvia miltiorrhiza ameliorates carbon tetrachloride-mediated
hepatic apoptosis in rats. J Pharm Pharmacol 2006;58:659e65.
20. Abdel Salam OM, Mohammed NA, Sleem AA, Farrag AR. The effect of
antidepressant drugs on thioacetamide-induced oxidative stress. Eur Rev
Med Pharmacol Sci 2013;17:735e44.
21. Salama SM, Abdulla MA, AlRashdi AS, Ismail S, Alkiyumi SS,
Golbabapour S. Hepatoprotective effect of ethanolic extract of Curcuma
longa on thioacetamide induced liver cirrhosis in rats. BMC Complement
Altern Med 2013;13:56.
22. Al-Attar AM. Attenuating effect of Ginkgo biloba leaves extract on liver
fibrosis induced by thioacetamide in mice. J Biomed Biotechnol
2012;2012:761450.
23. Anbarasu C, Rajkapoor B, Bhat K, Giridharan J, Amuthan AA, Satish K.
Protective effect of Pisonia aculeata on thioacetamide induced hepato-
toxicity in rats. Asian Pac J Trop Biomed 2012;2:511e5.
24. Arauz J, Moreno MG, Corte´s-Reynosa P, Salazar EP, Muriel P. Coffee
attenuates fibrosis by decreasing the expression of TGF-b and CTGF in a
murine model of liver damage. J Appl Toxicol 2013;33:970e9.
25. Li J, Li J, Li S, He B, Mi Y, Cao H, et al. Ameliorative effect of grape seed
proanthocyanidin extract on thioacetamide-induced mouse hepatic
fibrosis. Toxicol Lett 2012;213:353e60.
26. Nissar AU, Farrukh MR, Kaiser PJ, Rafiq RA, Afnan Q, Bhushan S, et al.
Effect of N-acetyl cysteine (NAC), an organosulfur compound from
Allium plants, on experimentally induced hepatic prefibrogenic events in
Wistar rat. Phytomedicine 2013;20:828e33.
27. Develi-Is S, Bekpinar S, Kalaz EB, Evran B, Unlucerci Y, Gulluoglu M,
et al. The protection by heme oxygenase-1 induction against
thioacetamide-induced liver toxicity is associated with changes in arginine
and asymmetric dimethylarginine. Cell Biochem Funct 2013;31:122e8.
28. Kantah MK, Kobayashi R, Sollano J, Naito Y, Solimene U, Jains S, et al.
Hepatoprotective activity of a phytotherapeutic formula on thio-
acetamidedinduced liver fibrosis model. Acta Biomed 2011;82:82e9.
